People · Operator
Named in public records as an officer, director or promoter · active 2016–2017 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| LogicBio Therapeutics, Inc. | — | Biotechnology | Series B | $33.2M | $1.2B | 2016 |
Mark A. Kay at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark A. Kay on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Leon A. Chen | 1 | 2 |
| Erez A. Chimovits | 1 | 1 |
| Adi Barzel | 1 | 1 |
| MARC A. RUBENSTEIN | 1 | 1 |
| TOMER A. KARIV | 1 | 1 |
| SOFIA A. IOANNIDOU | 1 | 1 |
| DANIEL A. O'CONNELL | 1 | 1 |
| Leszek Lisowski | 1 | 1 |
| FREDERIC A. CHEREAU | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.